Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
GILD
GILD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GILD News
Gilead Secures Regulatory Approval for Arcellx Acquisition
2d ago
Newsfilter
Gilead Extends Tender Offer Deadline for Arcellx Acquisition
2d ago
seekingalpha
Jim Cramer's Insights on Stocks
3d ago
Newsfilter
Gilead Sciences and Nokia Stock Outlook Analysis
3d ago
CNBC
Gilead Expands Access to HIV Prevention Drug Lenacapavir
5d ago
Newsfilter
Morgan Stanley Raises Gilead Price Target to $175, Maintains Overweight Rating
Apr 11 2026
Yahoo Finance
European Pharma Industry Faces Competitive Pressures
Apr 11 2026
CNBC
MGNX Positioned for Growth in Antibody-Drug Conjugate Market
Apr 10 2026
stocktwits
Gilead Sciences Accelerates Deal-Making Activity
Apr 10 2026
seekingalpha
Tempus Expands Collaboration with Gilead to Enhance Oncology Pipeline
Apr 09 2026
Newsfilter
TEMPUS FORGES STRATEGIC PARTNERSHIP WITH GILEAD TO ENHANCE ONCOLOGY RESEARCH AND DEVELOPMENT USING REAL-WORLD EVIDENCE
Apr 09 2026
moomoo
CARTOGRAPHY BIOSCIENCES: STRATEGIC ONCOLOGY PARTNERSHIP WITH GILEAD'S INITIAL TARGET OPTION EXERCISE ADVANCES
Apr 09 2026
moomoo
KYMERA THERAPEUTICS INC - GILEAD TO PROGRESS KT-200 INTO STUDIES PREPARING FOR IND FILING IN 2027
Apr 09 2026
moomoo
KYMERA THERAPEUTICS REVEALS GILEAD SCIENCES HAS EXERCISED OPTION TO LICENSE KT-200, AN ORAL CDK2 MOLECULAR GLUE DEGRADER CANDIDATE
Apr 09 2026
moomoo
GILEAD: TRUIST SECURITIES INCREASES TARGET PRICE TO $155, UP FROM $152
Apr 08 2026
moomoo
Gilead Acquires Tubulis to Expand ADC Capabilities
Apr 07 2026
stocktwits
Show More News
